Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Has $436,000 Stock Position in CVS Health Co. (NYSE:CVS)

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA trimmed its holdings in shares of CVS Health Co. (NYSE:CVS) by 2.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 9,723 shares of the pharmacy operator’s stock after selling 228 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in CVS Health were worth $436,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. MidAtlantic Capital Management Inc. bought a new stake in shares of CVS Health in the third quarter valued at approximately $25,000. Livelsberger Financial Advisory bought a new stake in shares of CVS Health during the 3rd quarter valued at $31,000. Legacy Investment Solutions LLC acquired a new stake in shares of CVS Health during the 3rd quarter worth $31,000. Reston Wealth Management LLC acquired a new position in CVS Health in the third quarter valued at about $32,000. Finally, Kathleen S. Wright Associates Inc. bought a new stake in CVS Health during the third quarter worth about $33,000. Institutional investors own 80.66% of the company’s stock.

Analyst Upgrades and Downgrades

CVS has been the subject of several analyst reports. Wells Fargo & Company upgraded shares of CVS Health from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $60.00 to $66.00 in a research report on Monday, November 18th. Deutsche Bank Aktiengesellschaft upgraded CVS Health from a “hold” rating to a “buy” rating and set a $66.00 target price for the company in a research note on Tuesday, December 3rd. UBS Group boosted their price target on CVS Health from $60.00 to $62.00 and gave the stock a “neutral” rating in a report on Thursday, November 7th. Mizuho reduced their price objective on CVS Health from $73.00 to $66.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Finally, Edward Jones raised CVS Health from a “hold” rating to a “buy” rating in a research note on Thursday, January 30th. One analyst has rated the stock with a sell rating, six have given a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $68.12.

CVS Health Stock Down 0.5 %

Shares of CVS opened at $53.95 on Monday. The stock’s 50-day moving average price is $50.79 and its two-hundred day moving average price is $55.99. CVS Health Co. has a 12 month low of $43.56 and a 12 month high of $80.75. The company has a market capitalization of $67.90 billion, a PE ratio of 13.69, a PEG ratio of 0.60 and a beta of 0.61. The company has a current ratio of 0.80, a quick ratio of 0.59 and a debt-to-equity ratio of 0.80.

CVS Health Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, February 3rd. Investors of record on Thursday, January 23rd were issued a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 4.93%. The ex-dividend date was Thursday, January 23rd. CVS Health’s payout ratio is presently 67.51%.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.